By [Andrew Warshauer](/content/author/andrew/ "Posts by Andrew Warshauer"/index.html)

Posted March 7, 2014

In

Analysis Only – De Novo

Content Overview

This article discusses the analysis only service offered by Cofactor Genomics, providing insights on their methodologies and applications in genomic research.

Key Points

• Service Description: Overview of what the Analysis Only service entails and how it benefits clients in genomic analysis.
• Methodologies Used: Description of the technologies and techniques employed by Cofactor Genomics in their analysis.
• Applications: Examples of scenarios where this service could be beneficial to researchers and healthcare professionals.

Cofactor Genomics, Inc. Announces CEO Transition in Preparation for Accelerated Commercial Growth and Increased Patient Access for OncoPrism, its Medicare Approved Immunotherapy Test

Cofactor Genomics expands clinical use of OncoPrism, as their AI enabled RNA test achieves national clinical validation after predicting immunotherapy response in Lung Cancer Patients

Cofactor Genomics Publishes Clinical Validation of OncoPrism-HNSCC, a Test Leveraging Novel RNA Modeling Technology to Predict Response to Immunotherapy

Precision Medicine Global Thought Leader, Dr. Howard McLeod, Joins Cofactor Genomics’ Advisory Board as Cofactor Brings OncoPrism test to Partnered Hospitals

Conclusion

This analysis serves to provide researchers and gene therapy practitioners with essential information on the capabilities of Cofactor Genomics’ services and their impact on the medical field.